Philadelphia, US, and Nottingham, UK, 27th June 2017: QS Pharma, the Contract Development and Manufacturing Organisation (CDMO), which was acquired by Quotient Clinical (“Quotient”) in February 2017, today announced it has received approval from the European Medicines Agency (EMA) to manufacture certain medicinal products for commercial use in Europe.
QS Pharma’s manufacturing facility in Boothwyn, Pennsylvania was inspected in February 2017 by the Dutch Health Care Inspectorate (IGZ) at the request of the EMA. The assessment focused on two NDA filed products, and the overall quality systems of QS Pharma. Following the successful outcome of the inspection, added to past approvals from the FDA and PDMA, QS Pharma is now approved to manufacture medicinal products for the US, Europe and Japan.
Nutan Gangrade, Managing Director, QS Pharma, said: “QS Pharma is dedicated to maintaining a robust quality system, underpinned by our excellent regulatory history. This approval by the EMA ensures we are able to support customers with interests in Europe, creating further growth opportunities for the business.”
Mark Egerton, Chief Executive Officer, Quotient Clinical, said: “QS Pharma is becoming a major global player in the commercial manufacture of market products, with a focus on high potency manufacturing, and niche therapies and markets such as orphan drugs, for tablets, capsules and oral liquids. This latest inspection and approval adds further value to the business.”
To find out more about QS Pharma, please click here.
To find out more about Quotient Clinical, please click here.